Edition:
United States

Navidea Biopharmaceuticals Inc (NAVB.A)

NAVB.A on American Stock Exchange

0.71USD
2 Dec 2016
Change (% chg)

$-0.01 (-1.85%)
Prev Close
$0.72
Open
$0.71
Day's High
$0.72
Day's Low
$0.70
Volume
38,587
Avg. Vol
170,378
52-wk High
$1.52
52-wk Low
$0.26

Select another date:

Wed, Nov 23 2016

BRIEF-Navidea Biopharmaceuticals enters asset purchase agreement with Cardinal Health

* Press release - Navidea signs asset purchase agreement with Cardinal Health

BRIEF-Navidea Biopharmaceuticals Q3 EPS $0.00

* Q3 revenue $8.5 million Source text for Eikon: Further company coverage:

BRIEF-Navidea Biopharma says appoints Michael Goldberg, M.D. as CEO

* Says appoints Michael M. Goldberg, M.D. president and chief executive officer

BRIEF-Navidea achieves $1 mln in Lymphoseek commercial milestones

* Navidea achieves $1 million in Lymphoseek commercial milestones

BRIEF-Navidea enters into letter of intent with cardinal health for sale of Lymphoseek in North America

* Navidea Biopharmaceuticals enters into letter of intent with cardinal health for the sale of Lymphoseek in North America

BRIEF-Navidea Biopharmaceuticals Q2 loss per share $0.04

* Continuing to explore alternative financing arrangements in order to refinance crg debt

BRIEF-Navidea gets IRB nod for Lymphoseek rheumatoid arthritis trial protocol

* Navidea receives IRB approval for its Lymphoseek rheumatoid arthritis clinical trial protocol

Select another date: